Carrollton-based RealTime Laboratories has been acquired by US BioTek Laboratories, a Seattle, Washington-based Clinical Laboratory Improvement Amendments and CAP accredited laboratory.
RealTime Laboratories is a pioneer in the field of testing for mycotoxins—hazardous toxins from mold. The deal expands the capabilities, expertise, and geographic footprint of the combined organization, providing more testing options to customers and accelerating the development of new diagnostic tests.
“This marks an exciting opportunity for RealTime and its employees,” RealTime CEO Dave Murcott said in a statement. “By combining forces with another leading provider of specialty medical testing services, it allows us the ability to expand our services and reach a wider audience. We are committed to providing our employees with new opportunities for growth and development, and we believe that this will help us achieve that goal.”
Terms of the deal were not disclosed.
Founded in 2005, RealTime Laboratories is a CAP and CLIA accredited clinical and environmental diagnostic laboratory that specializes in testing for and identifying mycotoxins—hazardous toxins from mold—in humans, houses, and animals, as well as infectious diseases.
The company said it has earned a reputation for having the most accurate and comprehensive mycotoxin test on the market. The acquisition will enable US BioTek to incorporate RealTime Laboratories’ state-of-the-art technology and expertise into its offerings.
“By joining forces, we can provide our clients with a more comprehensive suite of diagnostic testing services,” Jack Frausing, CEO of US BioTek Laboratories, said in a statement. “It will also position us for continued growth, innovation, and expansion of our test portfolio in the years to come. We’re confident that it will benefit our clients, their patients, and our employees.”
The two laboratories will continue operations at their respective locations in Seattle and Carrollton.
Get on the list.
Dallas Innovates, every day.
Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.
R E A D N E X T
-
The report by the Fort Worth Star-Telegram cites records filed with the city, with Alcon's potential new 250,000-SF manufacturing facility slated for a 135-acre site east of Alcon's campus, along East Altamesa Boulevard.
